Jul 11, 2016 1 min read

CANONSBURG – Mylan N.V. on Monday announced the U.S. launch of Temozolomide capsules, a generic version of Merck’s Temodar. Mylan, which has its administrative headquarters in Southpointe, received final approval from the U.S. Food and Drug Administration for the product, which is available in 5-, 20-, 100-, 140-, 180- and 250-milligram capsules. The medicine is indicated for the treatment of adult patients with newly diagnosed cancerous tumors known as glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment.

Temodar had U.S. sales of approximately $176.5 million for the 12 months ending May 31, according to IMS Health.